Question 1

What is Skytrofa?

Accepted Answer

Skytrofa is a long-acting prodrug of somatropin, which is a human growth hormone. It is designed to provide a sustained release of the hormone into the body over time.

This medication works by mimicking the effects of the growth hormone naturally produced by the pituitary gland. By providing a steady supply of this hormone, it helps support various physiological processes related to growth and development.

Question 2

What is Skytrofa used for?

Accepted Answer

Skytrofa is used to treat pediatric growth hormone deficiency .

Question 3

How does Skytrofa work?

Accepted Answer

Mechanism of Action

Skytrofa is a prodrug of somatropin, which is a human growth hormone. It is designed using technology that attaches the hormone to a carrier molecule, allowing it to be released gradually after injection. This slow-release mechanism enables the medication to maintain steady levels of growth hormone in the body over the course of a week.

How it Stimulates Growth

Once the active somatropin is released into the bloodstream, it binds to growth hormone receptors on various tissues. This interaction stimulates the production of insulin-like growth factor-1 (IGF-1), a hormone primarily made in the liver that is essential for growth. Together, these hormones promote several biological effects:

Bone Growth: They stimulate the growth plates in long bones, which helps children with growth hormone deficiency increase their height.

Tissue Development: They encourage the growth of skeletal muscles and internal organs.

Metabolism: They play a role in how the body processes proteins, fats, and carbohydrates.

By replacing the growth hormone that the body is not producing enough of on its own, Skytrofa helps support normal physical development and metabolic function.

Question 4

What are the active ingredients in Skytrofa?

Accepted Answer

The active ingredient in Skytrofa is lonapegsomatropin .

Question 5

What are the side effects of Skytrofa?

Accepted Answer

Common side effects of Skytrofa may include:

injection site reactions

headache

joint pain

Always consult with a healthcare professional about potential side effects.

Question 6

What drug class is Skytrofa?

Accepted Answer

Skytrofa belongs to the growth hormone analog drug class.

Question 7

What is the dosage of Skytrofa and how do I take it?

Accepted Answer

How to Use Skytrofa

Skytrofa is given as a subcutaneous injection, which means it is injected into the fatty tissue just under the skin. It is typically administered once weekly on the same day each week. The injection can be given at any time of day, with or without food.

The medication is supplied in a single-dose cartridge that must be used with a specific auto-injector device. The auto-injector automatically mixes the medicine inside the cartridge. Before administration, the cartridge should be removed from the refrigerator and allowed to reach room temperature.

Common injection sites include the abdomen, thighs, or buttocks. It is important to rotate the injection site with each dose to help prevent skin problems. Do not inject into areas where the skin is tender, bruised, red, or hard.

Missed Doses

If a dose is missed, it should be taken as soon as possible if only a short time has passed since the scheduled day. If several days have passed, skip the missed dose and wait until the next regularly scheduled day to take the next dose. Do not take two doses at the same time to make up for a missed one. There should be a sufficient number of days between any two doses as directed by a healthcare provider.

Question 8

Is Skytrofa safe during pregnancy and breastfeeding?

Accepted Answer

Pregnancy

There are no adequate or well-controlled studies regarding the use of Skytrofa in pregnant women. It is currently unknown whether the medication can cause harm to an unborn baby or affect a person's ability to become pregnant. Additionally, animal reproduction studies have not been conducted with this specific drug.

If you are pregnant or planning to become pregnant, you should discuss the potential risks and benefits of this treatment with your healthcare provider. Skytrofa should be used during pregnancy only if the potential benefit clearly outweighs the potential risk to the fetus.

Breastfeeding

It is not known if Skytrofa passes into human breast milk, how it might affect a nursing infant, or if it has any impact on milk production. While the active growth hormone in the medication is known to be present in human milk, it is generally considered unlikely to be absorbed by the infant's digestive system.

If you are breastfeeding or planning to breastfeed, consult your doctor to determine the safest course of action for you and your child. Decisions regarding treatment while breastfeeding should consider the importance of the drug to the mother and the potential effects on the infant.

Question 9

What forms and strengths does Skytrofa come in?

Accepted Answer

Skytrofa is supplied as a sterile, preservative-free powder contained within a dual-chamber prefilled cartridge. This cartridge is designed for use with a specific auto-injector device.

The medication is prepared by mixing the powder with the included diluent within the cartridge before administration. Each cartridge is intended for a single dose only and is administered via subcutaneous injection.

Question 10

What is the FDA approval status of Skytrofa?

Accepted Answer

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Skytrofa in August 2021. It is indicated for the treatment of pediatric patients 1 year of age and older who weigh at least 11.5 kg (approximately 25.4 pounds) and have growth failure due to inadequate secretion of endogenous growth hormone.

Regulatory Status

Skytrofa is a prodrug of somatropin designed for once-weekly subcutaneous injection. It is not currently subject to a boxed warning or a Risk Evaluation and Mitigation Strategy (REMS) program.

Safety Monitoring

The FDA monitors the safety of approved medications through the FDA Adverse Event Reporting System (FAERS). In early 2024, the FDA identified a potential signal of serious risk regarding adrenal insufficiency and hypoadrenalism associated with lonapegsomatropin-tcgd. The agency is currently evaluating the need for regulatory action, such as potential updates to the product labeling.

Question 11

What should I know about Skytrofa and cost?

Accepted Answer

Factors Affecting Cost

The price of Skytrofa can vary based on several factors. Because it is a specialty medication, it is typically obtained through specialty pharmacies rather than standard retail pharmacies. The total cost may be influenced by:

Insurance Coverage: Your out-of-pocket expenses will depend on your specific health insurance plan, including your deductible, copay, or coinsurance requirements.

Prior Authorization: Most insurance providers require prior authorization before they will cover Skytrofa. This process involves your healthcare provider submitting documentation to prove the medical necessity of the drug.

Dosage: The prescribed dose and the number of cartridges needed per month will affect the overall cost.

Generic Availability

Skytrofa is a brand-name medication. There is currently no generic version available. Brand-name drugs are generally more expensive than generic alternatives.

Financial Assistance

Financial support may be available to help manage the cost of Skytrofa. These programs are often provided by the manufacturer and may include:

Copay Cards: Patients with commercial insurance may be eligible for copay savings cards that reduce the amount paid at the pharmacy.

Patient Assistance Programs: These programs may provide the medication at a reduced cost or for free to individuals who meet specific income requirements or who do not have insurance coverage.

Skytrofa

Medication Quick Facts

📋Overview

What It's Used For

How It Works

Side Effects

Warnings & Precautions

Dosage & How to Take

Pregnancy & Breastfeeding

Forms & Strengths

FDA / Regulatory Status

Price Information

FAQ

Found an Error?